← Back to Search

H2 Receptor Antagonist

Famotidine 20 MG for Pulmonary Arterial Hypertension (REHAB-PH Trial)

Phase 2
Waitlist Available
Led By Peter J Leary, MD, PhD
Research Sponsored by University of Washington
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 0 to 24 weeks
Awards & highlights

REHAB-PH Trial Summary

This trial will test whether the drug famotidine is safe and effective in treating pulmonary arterial hypertension.

Eligible Conditions
  • Pulmonary Arterial Hypertension
  • Heart Failure

REHAB-PH Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~0 to 24 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 0 to 24 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Six-minute walk distance
Secondary outcome measures
BNP
Frequency of escalation for PAH focused care (increased diuretics, escalating doses of pulmonary vasodilators, and/or adding additional pulmonary vasodilators)
Health related quality of life (emPHasis-10 questionnaire)
+2 more
Other outcome measures
Cardiopulmonary Exercise Testing (sub-study): Exercise
Cardiopulmonary Exercise Testing (sub-study): Maximal oxygen uptake
Invasive hemodynamics (sub-study): Hemodynamics
+1 more

REHAB-PH Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: FamotidineExperimental Treatment1 Intervention
20mg of oral famotidine (pill) daily Other names: Pepcid
Group II: PlaceboPlacebo Group1 Intervention
Daily oral placebo (pill)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Famotidine
FDA approved

Find a Location

Who is running the clinical trial?

University of WashingtonLead Sponsor
1,749 Previous Clinical Trials
1,838,564 Total Patients Enrolled
1 Trials studying Pulmonary Arterial Hypertension
60 Patients Enrolled for Pulmonary Arterial Hypertension
National Heart, Lung, and Blood Institute (NHLBI)NIH
3,847 Previous Clinical Trials
47,818,156 Total Patients Enrolled
25 Trials studying Pulmonary Arterial Hypertension
3,071 Patients Enrolled for Pulmonary Arterial Hypertension
Peter J Leary, MD, PhDPrincipal InvestigatorUniversity of Washington
~13 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top